Bolt Biotherapeutics, Inc.
BOLT
$4.28
$0.081.79%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.87% | -- | 90.10% | 41.49% | -76.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.87% | -- | 90.10% | 41.49% | -76.83% |
| Cost of Revenue | -50.11% | -57.45% | -52.59% | -51.42% | -40.87% |
| Gross Profit | 42.79% | 78.77% | 65.47% | 59.78% | 22.41% |
| SG&A Expenses | -26.85% | -21.03% | -12.16% | -27.86% | -34.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.81% | -48.27% | -43.86% | -45.76% | -40.37% |
| Operating Income | 37.26% | 64.23% | 53.15% | 51.61% | 29.12% |
| Income Before Tax | 34.38% | 58.39% | 52.93% | 59.61% | -2.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.38% | 58.39% | 52.93% | 59.61% | -2.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.38% | 58.39% | 52.93% | 59.61% | -2.12% |
| EBIT | 37.26% | 64.23% | 53.15% | 51.61% | 29.12% |
| EBITDA | 36.86% | 64.90% | 53.68% | 52.29% | 29.57% |
| EPS Basic | 25.15% | 53.88% | 53.09% | 59.84% | -1.40% |
| Normalized Basic EPS | 25.15% | 61.14% | 53.09% | 51.72% | 29.21% |
| EPS Diluted | 25.15% | 53.88% | 53.09% | 59.84% | -1.40% |
| Normalized Diluted EPS | 25.15% | 61.14% | 53.09% | 51.72% | 29.21% |
| Average Basic Shares Outstanding | -12.34% | -9.77% | 0.36% | 0.58% | 0.71% |
| Average Diluted Shares Outstanding | -12.34% | -9.77% | 0.36% | 0.58% | 0.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |